Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

Ying-Hui Jin; Xian-Tao Zeng; Tong-Zu Liu; Zhi-Ming Bai; Zhong-Ling Dou; De-Gang Ding; Zhi-Lu Fan; Ping Han; Yi-Ran Huang; Xing Huang; Ming Li; Xiao-Dong Li; Yi-Ning Li; Xu-Hui Li; Chao-Zhao Liang; Jiu-Min Liu; Hong-Shun Ma; Juan Qi; Jia-Qi Shi; Jian Wang; De-Lin Wang; Zhi-Ping Wang; Yun-Yun Wang; Yong-Bo Wang; Qiang Wei; Hai-Bo Xia; Jin-Chun Xing; Si-Yu Yan; Xue-Pei Zhang; Guo-You Zheng; Nian-Zeng Xing; Da-Lin He; Xing-Huan Wang

doi:10.1186/s40779-022-00406-y

Your Location：

Home >

Browse articles >

Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

POSITION ARTICLE AND GUIDELINE | Updated：2023-05-10

- Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)
- Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)
- Military Medical Research 2023年10卷第2期页码：141-161
- Affiliations：
  
  1.Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  2.Department of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  3.Department of Urology, Haikou People's Hospital, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, China
  4.Department of Urology, the First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 450052, Henan, China
  5.Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China
  6.Department of Urology, the Second Hospital of Dalian Medical University, Dalian 116023, Liaoning, China
  7.Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
  8.Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200120, China
  9.Department of Urology, the People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830002, China
  10.Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China
  11.Institutes of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, Henan, China
  12.Department of Urology, the Second Affiliated Hospital and Second Clinical Medical College of Fujian Medical University, Quanzhou 362000, Fujian, China
  13.Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
  14.Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
  15.Department of Urology, Tianjin First Central Hospital, Tianjin 300190, China
  16.Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  17.Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
  18.Department of Urology, Qinghai University Affiliated Hospital, Xining 810012, China
  19.Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
  20.Department of Urology, Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Lanzhou 730030, China
  21.Department of Urology, Chifeng Cancer Hospital, the Second Affiliated Hospital of Chifeng University, Chifeng 024000, Inner Mongolia Autonomous Region, China
  22.Key Laboratory of Urinary Tract Tumors and Calculi, Department of Urology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian, China
  23.Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  24.Department of Urology, the Second Division of the First Hospital of Jilin University, Changchun 130061, China
  25.Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  26.Department of Urology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
- Author bio：
  
  * xingnianzeng@126.com;
  hedl@xjtu.edu.cn;
  wangxinghuan1965@163.com
- Funds：
  
  the National Key Research and Development Plan of China (Technology helps Economy 2020)(2016YFC0106300);the National Natural Science Foundation of China(82174230);Major Program Fund of Technical Innovation Project of Department of Science and Technology of Hubei Province(2016ACAl52)
- DOI：10.1186/s40779-022-00406-y
  中图分类号：
- 纸质出版：2023-04
- Accepted：
Scan QR Code
Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)[J]. Military Medical Research, 2023,10(2):141-161.

Cite this article as: Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44.
Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)[J]. Military Medical Research, 2023,10(2):141-161. DOI： 10.1186/s40779-022-00406-y.

Cite this article as: Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44. DOI： 10.1186/s40779-022-00406-y.

摘要

Abstract

Non-muscle invasive bladder cancer (NMIBC) is a major type of bladder cancer with a high incidence worldwide

resulting in a great disease burden. Treatment and surveillance are the most important part of NIMBC management. In 2018

we issued "Treatment and surveillance for non-muscle-invasive bladder cancer in China: an evidence-based clinical practice guideline" . Since then

various studies on the treatment and surveillance of NMIBC have been published. There is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in China. Developing a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore indicated. We formed a working group of clinical experts and methodologists. Through questionnaire investigation of clinicians including primary medical institutions

24 clinically concerned issues

involving transurethral resection of bladder tumor (TURBT)

intravesical chemotherapy and intravesical immunotherapy of NMIBC

and follow-up and surveillance of the NMIBC patients

were determined for this guideline. Researches and recommendations on the management of NMIBC in databases

guideline development professional societies and monographs were referred to

and the European Association of Urology was used to assess the certainty of generated recommendations. Finally

we issued 29 statements

among which 22 were strong recommendations

and 7 were weak recommendations. These recommendations cover the topics of TURBT

postoperative chemotherapy after TURBT

Bacillus Calmette–Guérin (BCG) immunotherapy after TURBT

combination treatment of BCG and chemotherapy after TURBT

treatment of carcinoma

in situ

radical cystectomy

treatment of NMIBC recurrence

and follow-up and surveillance. We hope these recommendations can help promote the treatment and surveillance of NMIBC in China

especially for the primary medical institutions.

关键词

Keywords

references

Lenis AT , Lec PM , Chamie K , Mshs MD . Bladder cancer: a review . JAMA. 2020 ; 324 ( 19 ): 1980 – 91 .

Richters A , Aben KKH , Kiemeney L . The global burden of urinary bladder cancer: an update . World J Urol. 2020 ; 38 ( 8 ): 1895 – 904 .

Zi H , He SH , Leng XY , Xu XF , Huang Q , Weng H , et al . Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019 . Mil Med Res. 2021 ; 8 ( 1 ): 60 .

Kamat AM , Hahn NM , Efstathiou JA , Lerner SP , Malmström PU , Choi W , et al . Bladder cancer . Lancet. 2016 ; 388 ( 10061 ): 2796 – 810 .

Taylor J , Becher E , Steinberg GD . Update on the guideline of guidelines: non-muscle-invasive bladder cancer . BJU Int. 2020 ; 125 ( 2 ): 197 – 205 .

Urological Association of Chinese Research Hospital Association (Crha) , Urological Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (Cpam) , Evidence-Based Medicine Association of China International Exchange and Promotive Association for Medical and Health Care (Cpam) , The Project Team for Minimally Invasive Plasma Kinetic System and Cloud Planning Solution of the National Key Research and Development Program of China . Treatment and surveillance for non-muscleinvasive bladder cancer in China: an evidence-based clinical practice guideline (2018 standard version) . J Modern Urol. 2019 ; 24 ( 7 ): 516 – 42 .

Guo YL , Na YQ , Ye ZQ , Huang J . Guidelines for diagnosis and treatment of urology and andrology in China . Beijing : Science Press ; 2019 .

Li CL . Standardization of cancer diagnosis and treatment series—bladder cancer and prostate cancer . Beijing : People's Medical Publishing House ; 2011 .

Chinese Urological Association of Chinese Medical Association , Chinese Bladder Cancer Consortium . Chinese consensus statements of second transurethral resection for non-muscle invasive bladder cancer . Chin J Urol. 2017 ; 38 ( 8 ): 561 – 3 .

Ma LL , Wang YY , Yang ZH , Huang D , Weng H , Zeng XT . Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020 ; 7 : 7 .

EAU . EAU-ESTRO-SIOG Guidelines on Non-muscle-invasive Bladder Cancer . https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ .

Brierley J , Gospodarowicz M , Wittekind C . TNM classification of malignant tumors . UICC International Union Against Cancer . 8th ed . New York : Wiley-Blackwell and UICC ; 2016 .

Moch H , Humphrey Pa , Ulbright Tm , Ve R . WHO Classification of Tumours of the Urinary System and Male Genital Organs , 4th ed . 2016 . https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016 https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016 .

Mostofi F , Sorbin L , Torloni H . Histologic typing of urinary bladder tumours. International classification of tumours, No 10 . Geneva : WHO ; 1973 .

Chang S , Bochner B , Chou R , Clark P . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline ( 2020 ). https://www.auanet.org/guidelines/guidelines/bladder-cancer-nonmuscle-invasive-guideline https://www.auanet.org/guidelines/guidelines/bladder-cancer-nonmuscle-invasive-guideline .

Bimal B , Ronald K , Girish S , Siemens D , Armen G . Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer 2021 . https://www.cua.org/system/files/Guidelines/7367_NMIBC%20Guideline_Epub.pdf https://www.cua.org/system/files/Guidelines/7367_NMIBC%20Guideline_Epub.pdf .

National Institute for Health and Care Excellence (Nice) . Bladder cancer: diagnosis and management . https://www.nice.org.uk/guidance/ng2 https://www.nice.org.uk/guidance/ng2 .

National Comprehensive Cancer Network (Nccn) . NCCN clinical practice guidelines in oncology: Bladder cancer . 2022 . https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417 .

Li H , Cao Y , Ma P , Ma Z , Li C , Yang W , et al . Novel visualization methods assisted transurethral resection for bladder cancer: an updated survivalbased systematic review and meta-analysis . Front Oncol. 2021 ; 11 : 644341 .

Cumberbatch MGK , Foerster B , Catto JWF , Kamat AM , Kassouf W , Jubber I , et al . Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review . Eur Urol. 2018 ; 73 ( 6 ): 925 – 33 .

Ali-el-Dein B , Nabeeh A , el-Baz M , Shamaa S , Ashamallah A . Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study . Br J Urol. 1997 ; 79 ( 5 ): 731 – 5 .

Barghi MR , Rahmani MR , Hosseini Moghaddam SM , Jahanbin M . Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder . Urol J. 2006 ; 3 ( 4 ): 220 – 4 .

The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer . Br J Urol. 1994 ; 73 ( 6 ): 632 – 8 .

De Nunzio C , Carbone A , Albisinni S , Alpi G , Cantiani A , Liberti M , et al . Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial . World J Urol. 2011 ; 29 ( 4 ): 517 – 21 .

Gudjónsson S , Adell L , Merdasa F , Olsson R , Larsson B , Davidsson T , et al . Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study . Eur Urol. 2009 ; 55 ( 4 ): 773 – 80 .

Messing EM , Tangen CM , Lerner SP , Sahasrabudhe DM , Koppie TM , Wood DP , et al . Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscleinvasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial . JAMA. 2018 ; 319 ( 18 ): 1880 – 8 .

Saika T , Tsushima T , Nasu Y , Miyaji Y , Saegusa M , Takeda K , et al . Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study . World J Urol. 2010 ; 28 ( 4 ): 413 – 8 .

Solsona E , Iborra I , Ricós JV , Monrós JL , Casanova J , Dumont R . Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow up . J Urol. 1999 ; 161 ( 4 ): 1120 – 3 .

Li NC , Ye ZQ , Na YQ , CUA THP® Immediate Instillations Study Group . Efficacy of immediate instillation combined with regular instillations of pirarubicinf or Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study . Chin Med J (Engl). 2013 ; 126 ( 15 ): 2805 – 9 .

Ueda T , Naito S , Iguchi A , Sagiyama K , Osada Y , Ariyoshi A , et al . Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group . Cancer Chemother Pharmacol. 1992 ; 30 ( Suppl ): S31 – 6 .

Shen J , Chen JH , Yu QW , Shen J , Sun P . Effect on prophase intravesical instillation of pirarubicin for preventing recurrence of bladder cancer . World Clin Durgs. 2011 ; 32 ( 5 ): 284 – 6 .

Chen YL , Ye LH , Tao SX , Qian SX . The therapeutic effects of intravesical instillation of mitomycin C immediately after TURBT for preventing recurrence of superficial bladder cancer . Zhejiang Clin Med J. 2003 ; 5 ( 10 ): 736 – 7 .

Li B , Lin Z , Li J , Qu Y . Comparison of THP high dose immediate perfusion and routine perfusion . Contemp Med. 2013 ; 19 ( 20 ): 35 – 6 .

Li J . Clinical study of immediate postoperative perfusion combined with distilled water irrigation for non-invasive urothelial carcinoma of bladder . World Latest Med Inform. 2017 ; 17 ( 10 ): 56 – 61 .

Li XD , Zhao EY , Wang CL , Xu WH . Clinical application of localization diagnosis and treatment in the early non-muscle invasive bladder cancer with THP . Prog Mod Biomed. 2011 ; 11 ( 21 ): 4106 – 8 .

Wang GQ . Intravesical instillation of pirarubicin after transurethral resection of bladder for superficial bladder cancer . J Clin Res. 2013 ; 30 ( 10 ): 2064 – 5 .

Wang JG , Zhang XJ , Chen SX , Yang GH , Ding SP , Zhou JJ , et al . A therapeutic effect analysis of the comparative early intravesical instillation of pirarubicin versus traditional intravesical instillation of pirarubicin for superficial bladder cancer . J Clin Urol. 2012 ; 27 ( 8 ): 588 – 90 .

Wang WM , Song YJ , Wang SC . Effect of early postoperative intravesical instillation of Pirarubicin on prevention of postoperative recurrence of bladder cancer . Henan J Surg. 2012 ; 18 ( 3 ): 61 – 2 .

Xu N , Xue XY , Zhou HL , Mao HP , Zheng QS , Wei Y , et al . Intravesical instillation of mitomycin C at different time after transurethral resection for the prophylaxis of superficial bladder cancer recurrence . Int J Urol Nephrol. 2008 ; 1 : 3 – 5 .

Yu J , Gong DX , Jiang YJ . The action on the recurrence of non-muscleinvasive bladder carcinoma using immediate and delayed instillation by hydroxycamptothecin . J Chin Med Univ. 2011 ; 40 ( 9 ): 851 .

Zhang HY , Song XW , Tian BY , Zhang GW , Guo RM , Li DC . Comparison of two different perfusion methods after resection of bladder tumor . Her Med. 2010 ; 29 ( 2 ): 205 – 6 .

Zhang HF . Clinical observation of postoperative bladder perfusion with pirarubicin for transurethral resection of superficial bladder cancer . Henan Med Res. 2017 ; 26 ( 14 ): 2609 – 10 .

Zhang JC , Li J , Zhu F , Zhang YJ . Intravesical instillation of THP immediately and regularly after transurethral resection of superficial bladder cancer . China Med. 2010 ; 5 ( 5 ): 431 – 2 .

Zhang YX , Tian K , Wang YL , Liu QZ , Yao DQ , Guo GF . Clinical significance of instantly intravesical instillation of pirarubicin for preventing recurrence of superficial bladder cancer after transurethral resection of bladder tumor . Chin J Pract Med. 2013 ; 40 ( 16 ): 45 – 7 .

Gu AZ , Zhu Q , Hu YS . Clinical effect of gemcitabine combined with pirarubicin intravesical chemotherapy for low-risk bladder cancer patients after operation . Chin J Pract Med. 2020 ; 47 ( 23 ): 97 – 100 .

Wu B , Wang XG , Shi HL , Mo NX , Lv Z . Clinical effect of gemcitabine intravesical instillation after resection of non-muscle invasive bladder cancer and its effect on immune function . Med J Commun. 2017 ; 31 ( 05 ): 450 – 2 .

Jiang BH , Cao QF , Feng QX . Clinical observation of gemcitabine irrigation after transurethral resection of non-muscle invasive bladder tumor in gerontal patients . J Pract Med. 2019 ; 35 ( 13 ): 2125 – 7 .

Wei C . Effect of intravesical instillation of gemcitabine on prevention of postoperative recurrence in patients with non muscle invasive bladder cancer . Med Front. 2017 ; 7 ( 16 ): 76 – 7 .

Xiao CS . Effect of intravesical instillation of gemcitabine on prevention of postoperative recurrence of bladder cancer without muscle infiltration . Strait Pharm J. 2019 ; 31 ( 5 ): 105 – 7 .

Wei C , Yu Y , Ni LL , Yang HS , Yang YH . Clinical efficacy of transurethral plasmakinetic resection combined with gemcitabine bladder perfusion therapy in treatment of non muscle invasive bladder cancer . Chin Foreign Med Res. 2021 ; 19 ( 4 ): 130 – 2 .

Liu DC , Shi HB , Chen B . A comparative study of intravesical instillation of gemcitabine and pirarubicin in the treatment of bladder cancer . Pract J Cancer. 2018 ; 33 ( 2 ): 328 – 30 .

Zhang GP , Lei G , Wang L , Zhang TD , Mu JJ , Bai B , et al . Efficacy and safety of gemcitabine intravesical instillation in the treatment of non-myometrial invasive bladder cancer . Sichuan Medl J. 2018 ; 39 ( 11 ): 1246 – 9 .

Huang J , Xiong JY . Clinical study of gemcitabine used for intravesical instillation . Chin Mod Dr. 2018 ; 56 ( 36 ): 82 – 4 .

Sun J , Sun CW , Ding XQ . Observation of recurrence and survival of superficial bladder cancer treated by plasma electrocision combined with gemcitabine intravesical instillation . Guizhou Med J. 2018 ; 42 ( 3 ): 299 – 301 .

Zhang JJ , Cai WQ , Zhang SQ , Fang XL . Comparison of efficacy between intra-bladder perfusion with gemcitabine and pirarubicin for preventing postoperative recurrence of non-muscle invasive bladder cancer . Guangxi Med J. 2016 ; 38 ( 09 ): 1260 – 2 .

Zhang JJ , Hao L , Shi ZY , Pang K , Dong Y , Han CH . Intravesical instillation of gemcitabine and pirarubicin for prevention of postoperative recurrence of non muscle invasive bladder cancer . J Clin Med Lit (Electron Ed). 2017 ; 4 ( 47 ): 9250 .

Qin KS , Li JQ . Effect of intravesical instillation chemotherapy with gemcitabine on transurethral resection of bladder cancer . Mod Diagn Treat. 2019 ; 30 ( 3 ): 465 – 7 .

Li LJ , Ma ZW , Gong BS , Qiu MX . Application of gemcitabine in high risk non muscle invasive bladder cancer after two transurethral resection . Mod Med Health. 2016 ; 32 ( 16 ): 2560 – 1 .

Kong LQ , Yu QC , Yang M , Qu YL . Effect of gemcitabine and pirarubicin infusion on recurrence after bladder cancer surgery . Med J Qilu. 2016 ; 31 ( 3 ): 282 – 4 .

Wang LC . Effect of intravesical instillation chemotherapy with gemcitabine on patients with bladder cancer undergoing transurethral resection of the tumor . Contemp Med Forum. 2016 ; 14 ( 22 ): 7 – 8 .

Hu P , Li G . Comparison of gemcitabine and pirarubicin instillation of bladder for bladder cancer . J Clin Ration Drug Use. 2019 ; 12 ( 26 ): 10 – 1 .

Cai Q , Wang ZS , Zhang W , Cao JJ . Comparison of gemcitabine and pirarubicin after single time intravesical instillation chemotherapy in the treatment of low risk bladder cancer . Zhejiang J Integr Tradit Chin West Med. 2019 ; 29 ( 6 ): 500 – 2 .

Dong SF . Effect of pirarubicin and gemcitabine intravesical chemotherapy on the recurrence and postoperative survival of bladder cancer patients . Chin J Clin Oncol Rehabil. 2016 ; 23 ( 7 ): 839 – 41 .

Feng SQ , Fan HT , Ren M , Zhang M . Clinical research of postoperative intravesical instillation of gemcitabine to prevent recurrence of bladder cancer (Report of 198 cases) . J Clin Urol. 2014 ; 29 ( 11 ): 977 – 9 .

Jiang T , Wang DG , Jiang B , Yang Y , Guo J , Zhang JR , et al . The clinical study of the safety and tolerance of using gemcitabine in bladder perfusion Immediately after transurethral resection of bladder tumor . Med Philos. 2016 ; 37 ( 7 ): 44 – 6 .

Xu T , Li JT , Yang DJ , Su YD , Li JJ . Study of gemcitabine intravesical chemotherapy . Pract Pharm Clin Rem. 2016 ; 19 ( 8 ): 949 – 51 .

Cheng WB , Zhang N , Li Q . The value of gemcitabine perfusion in elderly patients with non-myometrial invasive bladder tumor after transurethral resection . Clin Res. 2020 ; 28 ( 11 ): 14 – 6 .

Zhang XH , Tan J , Yao K , Wang JR , Wan B , Wei WS . Clinical effect of anticancer drug perfusion in preventing postoperative recurrence of superficial bladder cancer . J Chin Phys. 2015 ; 17 ( 7 ): 1043 – 5 .

Liu XY , Xiang CH , Chen SL . Curative efficacy of intravesical reperfusion with gemcitabine for preventing postoperative re-currence of nonmuscle invasive bladder cancer . Pract J Clin Med. 2018 ; 15 ( 1 ): 148 – 50 .

Zhang X , An RH , Yu JS , Yu SL , Gan XG . Pirarubicin preventive efficacy of superficial bladder cancer recurrence . Prog Mod Biomed. 2015 ; 15 ( 28 ): 5496 – 9 .

Dong XC , Song LD , Zhang F . Effect of intravesical infusion of different chemotherapeutic drugs on preventing tumor recurrence after TURBT . Zhejiang J Traum Surg. 2017 ; 22 ( 1 ): 109 – 10 .

He YF , Ma YT , Gao WJ . Efficacy and safety of intravesical chemotherapy with gemcitabine in preventing postoperative recurrence of non muscle invasive bladder cancer . Clin Res Pract. 2018 ; 3 ( 32 ): 68 – 9 .

Hu YQ , Wang XR , Xie MM , Zhao Y , Wang ZJ , Xu ML . The efficacy of intravesical chemotherapy for bladder cancer treat with pirarubicin and gemcitabine . J Mod Oncol. 2015 ; 23 ( 17 ): 2463 – 6 .

Liao YX , Zhou JJ , Yang GH , Zeng JM . Study on gemcitabine in the treatment of bladder cancer . J Contemp Urol Reprod Oncol. 2017 ; 9 ( 5 ): 266 – 9 .

Qiang YC , Li J . Efficacy and safety of hyperthermic bladder chemotherapy with gemcitabine after transurethral resection of bladder tumors in elderly with superficial bladder cancer . Shaanxi Med J. 2021 ; 50 ( 2 ): 184 – 7 .

Chen DP , Zhang Y . Comparison of the therapeutic effect of three drugs by bladder instillation after transurethral resection of superficial bladder cancer . J Mod Urol. 2008 ; 13 ( 2 ): 121 – 3 .

Tu FZ , Shen ZJ , Wang XJ , Zhong S , Zhu ZW , Wang HF , et al . The clinical investigation of different intravesical instillation of chemotherapy after transurethral resection of bladder tumors for the treatment of superficial bladder cancer . Int J Urol Nephrol. 2012 ; 32 ( 2 ): 193 – 6 .

Guan H , Li QW . Therapeutic comparison of bladder instillation with hydroxycamptothecine and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer . Chin J Anat Clin. 2015 ; 20 ( 1 ): 64 – 6 .

Tao JH , Jiang X . Efficacy of pirarubicin combined with hydroxycamptothecin in preventing recurrence after resection of bladder cancer . Lab Med Clin. 2015 ; 12 ( 4 ): 546 – 7 .

Long J , Lin HS , Mo ZN , Wei SC . Clinical effects of different intravesical instillation chemotherapies on non-muscle invasive bladder cancer after transurethral electroresection . Chin J New Clin Med. 2017 ; 10 ( 5 ): 447 – 9 .

Pu J , Wu XH , Tang W , Chen ZX , Wang DL , He YF . Clinical study of intravesical pirarubicin instillation for preventing postoperative recurrence of superficial bladder cancer . Chongqing Med J. 2009 ; 38 ( 17 ): 2163 – 4 .

Wang P . Clinical observation and analysis of intravesical instillation of three drugs to prevent postoperative recurrence of superficial bladder tumor . Qinghai University ; 2014 .

Mao WD , Wu JM , Zhang BZ , Zheng DY , Zhou JH , Xu YC , et al . Clinical efficacy of intravesical instillation of pirarubicin combined with Hydroxycamptothecin in the prevention and treatment of bladder cancer recurrence . Chin High Med Educ. 2012 ; 8 : 145 – 6 .

He XL , Qiang YY , Zhang BB , Song HX , Jin YS . Clinical effect of the pirarubicin in the treatment of non-muscle invasive bladder cancer . Int J Urol Nephrol. 2017 ; 37 ( 2 ): 196 – 9 .

Feng X . Efficacy of TURBT combined with hydroxycamptothecin and pirarubicin intravesical perfusion in the treatment of SBC and its relationship with clinical characteristics . Jinan University ; 2013 .

Li YX , Zhang KZ , Tang ZZ , Wu AM , Chi YY . THP and hydroxycamptothecin for prevention of postoperative superficial bladder cancer recurrence clinical analysis . Jilin Med J. 2013 ; 34 ( 24 ): 4873 – 4 .

Wang YH . Comparison of therapeutic effects of different perfusion drugs after electroresection of superficial bladder tumors . Med Inf. 2014 ; 27 ( 12 ): 124 – 5 .

Nan Y . Comparison of efficacy of intravesical instillation of hydroxycamptothecin and pirarubicin in preventing recurrence of non muscle invasive bladder cancer . Hainan Med J. 2014 ; 25 ( 23 ): 3539 – 40 .

Lou B , Song XX , Guo XD . Observation of recurrence prevention effect of pirarubicin after bladder cancer electrocision . Med Recapitul. 2011 ; 17 ( 11 ): 1740 – 1 .

Chen BK , Gao LP , Yu HY , Jiang WB , Wu SJ , Lv ZW , et al . Comparison the effect and safety of pirarubicin and mitomycin by bladder instillation for preventing postoperative recurrence on the superficial bladder cancer . Chin J Clin Pharm. 2010 ; 26 ( 10 ): 723 – 5 .

Gu DL . Effect of pirarubicin infusion on superficial bladder cancer and its adverse reaction . Tianjin Pharm. 2021 ; 33 ( 1 ): 60 – 2 .

Fang D . Clinical observation of bladder perfusion after transurethral resection of non muscle invasive bladder cancer . Taishan Medical University ; 2018 .

Teng DH , Zhang YG , Wang XF , Li J , Huang GM , Ao M , et al . Clinical research on prevention of recurrence of superficial bladder cancer by intravesical instillation of pirarubicin or mitomycin C after transurethral resection of bladder tumor . J Shanxi Med Univ. 2011 ; 42 ( 4 ): 341 – 3 .

Zhang HQ . Clinical study of intravesical instillation of pirarubicin to prevent recurrence of superficial bladder tumor . J Chin Phys. 2006 ; 8 ( 12 ): 1718 – 9 .

Li JH , Zhu SY . Effect of intravesical instillation of pirarubicin and mitomycin on postoperative recurrence of superficial bladder cancer . Chin J Clin Oncol Rehabil. 2012 ; 19 ( 5 ): 393 – 4 .

Ni JT , Dong YX , Gao XK . Comparison of effects of Mitomycin and Pirarubicin infusion chemotherapy in the treatment of non-muscle invasive bladder cancer after TURBT . Chin J Front Med Sci (Electron Version). 2018 ; 10 ( 11 ): 94 – 7 .

Ma J , Fan DB , Liao K . Comparison of the effect of different drugs by bladder instillation in treatment with superficial bladder cancer . Sichuan Med J. 2013 ; 34 ( 1 ): 104 – 5 .

Ye LH . Comparison of curative effect and nursing experience of pirarubicin and mitomycin intravesical instillation to prevent postoperative recurrence of superficial bladder cancer . Strait Pharma J. 2012 ; 24 ( 5 ): 178 – 80 .

Zhang LB , Yang ZY , Feng G , Shen L , Hu XL , Yang B . Clinical study of intravesical instillation of different drugs to prevent postoperative recurrence of superficial bladder tumor . J Clin Med Pract. 2017 ; 21 ( 3 ): 168 – 9 .

Yang MG , Zhao XK , Wu ZP , Xiao N , Lv C . Comparison of the therapeutic efficacy of benzalkonium bromide, pirarubicin, and mitomycin C in prevention of postoperative recurrence of superficial bladder cancer . Tumor. 2008 ; 28 ( 12 ): 1055 – 8 .

Yang NG , Wang SP , Wang J , Zhang J . Efficacy of pirarubicin and mitomycin infusion chemotherapy in the prevention of bladder tumor recurrence . Chin Mod Med. 2011 ; 18 ( 17 ): 77 – 8 .

Zhuang QH . Prognosis of transurethral resection of superficial bladder tumor combined with pirarubicin perfusion . Chin Health Ind. 2014 ; 2 : 129 – 30 .

Yin SS . Effect of transurethral resection of bladder tumor combined with intravesical instillation of Pirarubicin on postoperative recurrence rate and quality of life in patients with superficial bladder cancer . Contemp Med. 2016 ; 22 ( 18 ): 143 – 4 .

Zhu SL , Yang F . Comparation of the effect of bladder instillation with mitomycin C and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer . J Bengbu Med Coll. 2013 ; 38 ( 6 ): 729 – 31 .

Yang T , Li Y , Zhang PJ , Liu JJ , Sun FZ , Wang G . Comparative study of intravesical instillation of pirarubicin and mitomycin C in the prevention of recurrence of superficial bladder urothelial carcinoma after transurethral resection of bladder tumor . Mod J Integr Tradit Chin West Med. 2015 ; 24 ( 24 ): 2657 – 8 .

Wang T . Bi WH Clincal study on intravesical instillation of priarubicin (THP) for preventing postoperative recurrence of superficial bladder cancer . J Mod Oncol. 2015 ; 23 ( 16 ): 2330 – 2 .

Zheng XB , Zhan ZS . Clinical observation of pirarubicin infusion chemotherapy after TURBT for non muscle invasive bladder cancer . Shenzhen J Integr Tradit Chin West. 2018 ; 28 ( 13 ): 173 – 5 .

Fu Y . Transurethral resection of bladder tumor combined with intravesical instillation of pirarubicin in the treatment of superficial bladder cancer . Clin Res Pract. 2016 ; 1 ( 5 ): 25 .

Su ZQ . Comparative study of the efficacy in preventing the recurrence of superficial bladder cancer between intravesical pirarubicin(THP) and mitomycin(CMMC) . Hainan Med J. 2014 ; 25 ( 15 ): 2281 – 2 .

Kuroda M , Niijima T , Kotake T , Akaza H , Hinotsu S . Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer: the 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml . Eur Urol. 2004 ; 45 ( 5 ): 600 – 5 .

Liu B , Wang Z , Chen B , Yu J , Zhang P , Ding Q , et al . Randomized study of single instillation of epirubicin for superficial bladder carcinoma: longterm clinical outcomes . Cancer Invest. 2006 ; 24 ( 2 ): 160 – 3 .

Masters JR , Popert RJ , Thompson PM , Gibson D , Coptcoat MJ , Parmar MK . Intravesical chemotherapy with epirubicin: a dose response study . J Urol. 1999 ; 161 ( 5 ): 1490 – 3 .

Liu BC , Zhang YF , Wang Z , Ding Q , Chen B , Yu J , et al . Single intravesical instillation of epirubicin for primary superficial bladder carcinoma: long-term results . Chin J Urol. 2004 ; 25 ( 6 ): 380 – 2 .

Lv J , Wang JW . Cost-effectiveness analysis of epirubicin bladder perfusion in preventing postoperative recurrence of superficial bladder cancer . Chin Pharm. 2015 ; 20 : 48 – 9 .

Liang JM , Yang ZB , Wang XM , Mo LJ , Yu J . The clinical research on preventing the recurrence of superficial bladder cancer by intravesical infusion with epirubicin and mitomycin . J Guangxi Med Univ. 2015 ; 32 ( 3 ): 395 – 7 .

Zhang YF , Zhang ZB , Tang YZ , Liu BC , Sun FK , Tang H . Single or consecutive instillation of epirubicin or mitomycin C for the prophylaxis of recurrent primary superficial bladder carcinoma . Chin Oncol. 2000 ; 10 ( 3 ): 211 – 3 .

Wu ZB , Lin GB , Chen BJ , Wu ZM , Rong RM . Efficacy and safty of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence . Chin J Oncol. 2005 ; 08 : 507 – 9 .

Deng XJ , Li ZM , Li S , Li G , Huang WS , Shi GQ . Effectiveness and safety of different doses of pirarubicin on preventing non-muscle invasive bladder cancer recurrence by intravesical instillation . J Clin Urol. 2017 ; 32 ( 3 ): 226 – 8 .

Peng J , Pan M . Single bladder pirarubicin perfusion to prevent the recurrence of superficial bladder carcinoma . J Contemp Urol Reprod Oncol. 2011 ; 3 ( 3 ): 157 – 8 .

Lu JL , Xia QD , Lu YH , Liu Z , Zhou P , Hu HL , et al . Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis . Cancer Med. 2020 ; 9 ( 21 ): 7800 – 9 .

De Reijke TM , Kurth KH , Sylvester RJ , Hall RR , Brausi M , Van De Beek K , et al . Bacillus Calmette-Guerin versus epirubicin for primary. Secondary or concurrent carcinoma in situ of the bladder: results of a european organization for the research and treatment of Cancer-Genito-Urinary Group phase III trial (30906) . J Urol. 2005 ; 173 ( 2 ): 405 – 9 .

Di Lorenzo G , Perdonà S , Damiano R , Faiella A , Cantiello F , Pignata S , et al . Gemcitabine versus bacille Calmette–Guérin after initial bacille Calmette–Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial . Cancer. 2010 ; 116 ( 8 ): 1893 – 900 .

Fallah F , Fallah M , Sajadi Nia RS . Thiotepa versus bacille Calmette–Guérin in non-muscle invasive bladder cancer . Current Urol. 2012 ; 6 ( 3 ): 160 – 4 .

Gontero P , Oderda M , Mehnert A , Gurioli A , Marson F , Lucca I , et al . The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial . J Urol. 2013 ; 190 ( 3 ): 857 – 62 .

Hinotsu S , Akaza H , Naito S , Ozono S , Sumiyoshi Y , Noguchi S , et al . Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer . BJU Int. 2011 ; 108 ( 2 ): 187 – 95 .

Lamm DL , Blumenstein BA , Crawford ED , Montie JE , Scardino P , Grossman HB , et al . A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder . N Engl J Med. 1991 ; 325 ( 17 ): 1205 – 9 .

Lamm DL , Blumenstein BA , David Crawford E , Crissman JD , Lowe BA , Smith JA Jr , et al . Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study . Urol Oncol. 1995 ; 1 ( 3 ): 119 – 26 .

Lundholm C , Norlén BJ , Ekman P , Jahnson S , Lagerkvist M , Lindeborg T , et al . A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma . J Urol. 1996 ; 156 ( 2 Pt 1 ): 372 – 6 .

Martínez-Piñeiro JA , Jiménez León J , Martínez-Piñeiro L Jr , Fiter L , Mosteiro JA , Navarro J , et al . Bacillus Calmette–Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer . J Urol. 1990 ; 143 ( 3 ): 502 – 6 .

Melekos MD , Chionis HS , Paranychianakis GS , Dauaher HH . Intravesical 4’-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer . Cancer. 1993 ; 72 ( 5 ): 1749 – 55 .

Rintala E , Jauhiainen K , Alfthan O , Hansson E , Juusela H , Kanerva K , et al . Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer . Eur Urol. 1991 ; 20 ( 1 ): 19 – 25 .

van der Meijden AP , Brausi M , Zambon V , Kirkels W , de Balincourt C , Sylvester R . Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial . J Urol. 2001 ; 166 ( 2 ): 476 – 81 .

Vegt PD , Witjes JA , Witjes WP , Doesburg WH , Debruyne FM , van der Meijden AP . A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder . J Urol. 1995 ; 153 ( 3 Pt 2 ): 929 – 33 .

Witjes JA , van der Meijden AP , Witjes WP , Doesburg W , Schaafsma HE , Debruyne FM . A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder . Eur J Cancer. 1993 ; 29 ( 12 ): 1672 – 6 .

Li JX , Li JB , Zhang P , Lin SQ , Sun Y . Intravesical instillation of piarubicin for preventing postoperative recurrence of superficial bladder cancer . J Trop Med. 2009 ; 9 ( 7 ): 763 – 5 .

Xia JP , Deng LH , Xu XH , Tang CL . Clinical observation of preventing bladder cancer postoperative recurrence by BCG intravesical instillation combined with pirarubicin . Chin J Med Guide. 2011 ; 13 ( 3 ): 448 – 50 .

Pei L . Observation on the efficiency of different drugs by bladder instillation for prevention of recurrences in patients with superficial bladder carcinoma . Shanxi Med J. 2015 ; 44 ( 6 ): 634 – 5 .

Wang S , Yu JQ , Xia D , Shen BH , Jin BY , Chen SY , et al . Single-dose instillations of epirubicin as prophylaxis for recurrence of superficial bladder tumors: a prospective randomized controlled study . Chin J Urol. 2003 ; 24 ( 7 ): 454 – 6 .

Yu SY . Efficacy of mitoxantrone hydrochloride and BCG intravesical infusion in preventing tumor recurrence . Pract Pharm Clin Rem. 2011 ; 14 ( 1 ): 72 – 3 .

Yang WX , Shao YX , Hu X , Xiong SC , Liu Y , Li X . A randomized controlled study of intravesical instillation therapy of bacillus Calmette-Guérin vs. Epirubicinin treating non-muscular invasive bladder cancer . J Sichuan Univ (Med Sci Edition). 2021 ; 52 ( 2 ): 326 – 33 .

Ma WJ , Shao T , Shuang WB , Wang DW . A randomized controlled study of single intravesical instillation of pirarubicin in the prevention of postoperative recurrence of non myometrial invasive bladder urothelial carcinoma . Cancer Res Clin. 2009 ; 21 ( 4 ): 270 – 1 .

Wu XD , Yang XZ , Wang J . Observarion on the effect of THP, BCG by bladder instillation to prevent the recurrence of the bladder cancer . Int Med Health Guid News. 2006 ; 12 ( 8 ): 67 – 8 .

Ning YC . Comparison of two different intravesical chemotherapy efficacy in the prevention of superficial bladder cancer recurrence . World Latest Med Inf. 2013 ; 13 ( 9 ): 65 .

Kang YS , Sun DN , Wang Q , Yan JQ , Meng MS , Sun DD . Comparison between pirarubicin and BCG bladder instillation for prevention of superficial bladder cancer from recurrence . Med J Natl Defend Forces Southwest Chin. 2009 ; 19 ( 11 ): 1104 – 5 .

Shi ZY , Zhou SY , Yi HP . Comparison of the therapeutic effect of several drugs infused into the bladder for superficial tumors after transurethral resection of the bladder tumor . Chin Oncol. 2001 ; 11 ( 4 ): 328 – 30 .

Schmidt S , Kunath F , Coles B , Draeger DL , Krabbe LM , Dersch R , et al . Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer . Cochrane Database Syst Rev. 2020 ; 1 ( 1 ): CD011935 .

Li XY , Cai Y , Hu X , Wang YB , Wang YY , Jin YH , et al . Efficacy and safety of low dose and standard dose bacillus calmette guerin vaccine for non-muscle invasive bladder cancer: a meta-analysis . J Contemp Urol Reprod Oncol. 2021 ; 13 ( 3 ): 139 – 46 .

Oddens J , Brausi M , Sylvester R , Bono A , Van De Beek C , Van Andel G , et al . Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and highrisk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance . Eur Urol. 2013 ; 63 ( 3 ): 462 – 72 .

Qin DM , Yang JR , Li XH , Lou JA , Wang YY , Wang YB , et al . Efficacy of bacille Calmette-Guérin induction therapy and bacille Calmette-Guérin induction plus with maintenance therapy for postoperative non-muscle invasive bladder cancer: a systematic review and Meta-analysis . Chin J Front Med Sci (Electron Version). 2021 ; 13 ( 10 ): 57 – 66 .

Kamat AM , Lerner SP , O’donnell M , Georgieva MV , Yang M , Inman BA , et al . Evidence-based assessment of current and emerging bladdersparing therapies for non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta-analysis . Eur Urol Oncol. 2020 ; 3 ( 3 ): 318 – 40 .

Li R , Sundi D , Zhang J , Kim Y , Sylvester RJ , Spiess PE , et al . Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Guérin . Eur Urol. 2020 ; 78 ( 3 ): 387 – 99 .

Huang D , Jin YH , Weng H , Huang Q , Zeng XT , Wang XH . Combination of intravesical Bacille Calmette-Guérin and chemotherapy vs. Bacille Calmette-Guérin alone in non-muscle invasive bladder cancer: a metaanalysis . Front Oncol. 2019 ; 9 : 121 .

Arends TJ , Nativ O , Maffezzini M , De Cobelli O , Canepa G , Verweij F , et al . Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus Calmette-Guérin Ready to submit your research ? Choose BMC and benefit from: for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer . Eur Urol. 2016 ; 69 ( 6 ): 1046 – 52 .

Di Stasi SM , Giannantoni A , Stephen RL , Capelli G , Navarra P , Massoud R , et al . Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study . J Urol. 2003 ; 170 ( 3 ): 777 – 82 .

Droller D . Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder . J Urol. 2002 ; 168 ( 5 ): 2306 – 7 .

van Gils-Gielen RJ , Witjes WP , Caris CT , Debruyne FM , Witjes JA , Oosterhof GO . Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group . Urology. 1995 ; 45 ( 4 ): 581 – 6 .

Witjes JA , van Meijden AP , Collette L , Sylvester R , Debruyne FM , Van Aubel A , et al . Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group . Urology. 1998 ; 52 ( 3 ): 403 – 10 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)

Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" is necessary

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021

The emerging role of ferroptosis in the pathological development and progression of sepsis